WEE1
A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
Adavosertib showed activity in uterine serous carcinoma and TP53-mutant tumours but development was paused; azenosertib (ZN-c3) and Debio 0123 continue in ovarian and other cancers.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
- 1 · What it is
A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
- 2 · What goes wrong in cancer
Inhibits CDK1 to enforce the G2/M checkpoint; TP53-mutant cells depend on it.
- 3 · How drugs use it
No product in this corpus aims at WEE1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Biology
Inhibits CDK1 to enforce the G2/M checkpoint; TP53-mutant cells depend on it.
- TP53-mutant, CCNE1-amplified tumours
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Ovarian cancer | 15-20% | CCNE1 amplification (dependency context) | TP53 mutation ~95% | cBioPortal (TCGA) |
| Endometrial cancer | n/a | Uterine serous carcinoma context | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"WEE1" OR ABSTRACT:"WEE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about WEE1, not a curated reading list.